ProCE Banner Activity

CheckMate 577 Update: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer After Neoadjuvant Chemotherapy

Slideset Download
Conference Coverage
Compared with placebo, adjuvant nivolumab significantly prolonged disease-free survival in patients with resected EC/GEJC who had received neoadjuvant chemotherapy.

Released: June 17, 2021

Expiration: June 16, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme